Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaccinium myrtillus is a plant species in the Ericaceae family, commonly known as bilberry or European blueberry. The parts used medicinally include both the fruit and the leaves. Bilberry leaves and fruits are rich in polyphenols and anthocyanins, with other significant phytochemicals like hydroxycinnamic acids, flavanols, flavonols, tannins, triterpenes, and phytosterols. Mechanistically, it exhibits antimicrobial, antioxidant, anti-inflammatory, vasoprotective, and antidiabetic effects relating primarily to its phenolic and flavonoid content, which modulate pathways related to inflammation, oxidative stress, microvascular integrity, and bacterial adhesion. Traditionally, bilberry leaves are used for diabetes management, while the fruit is indicated for vision problems (e.g., retinopathy, cataracts, macular degeneration, night-blindness), venous insufficiency, diarrhea, and capillary fragility. The mechanisms of antimicrobial action include inhibition of bacterial cell wall adhesion, disruption of membrane integrity, and synergistic interactions with some antibiotics. The fruit is marketed as a standardized herbal medicine in Europe, and both leaf and fruit extracts feature as dietary supplements. There is no recognized pharmaceutical developer; primary indications are for eye health, venous disorders, and diabetes. Safety concerns are minimal, with rare allergic reactions and theoretical interactions with anticoagulants described[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vaccinium myrtillus.